Opthea's previous phase 2 trial had the best control efficacy ever seen in a trial for Lucentis so there was a high bar for success. It underlined their commentary that many trials conducted by other companies deliberately under dose the control arm to enhance thei results.
Opthea's previous phase 2 trial had the best control efficacy...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.045(6.43%) |
Mkt cap ! $806.3M | |||
| Open | High | Low | Value | Volume |
| 69.5¢ | 69.5¢ | 63.0¢ | $2.808M | 4.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49996 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 50869 | 6 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |